Product

Standard Chemo- or Endocrine Therapy

1 clinical trial

2 indications

Indication

HER2-negative Metastatic Breast Cancer

Indication

HER2-positive Circulating Tumor Cells

Clinical trial

DETECT III - A Multicenter, Randomized, Phase III Study to Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients With Initially HER2-negative Metastatic Breast Cancer and HER2-positive Circulating Tumor Cells

Status: Completed, Estimated PCD: 2022-01-01